Therapeutic allogeneic lymphocytes

DB17459InvestigationalCell transplant therapies

Therapeutic allogeneic lymphocytes: Overview.

Mechanism: Pharmacologically active on Myeloblastin, Interleukin-13 receptor subunit alpha-2, and Wilms tumor protein
Curator reviewed

Resolves to

Targets

What you can answer from here — as of July 08, 2026

5Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

59Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Therapeutic allogeneic lymphocytes, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.